Ophthalmological treatment of early-onset sarcoidosis/Blau syndrome in a Colombian child: A case report.

Am J Ophthalmol Case Rep

NeURos Research Group. Escuela de Medicina y Ciencias de La Salud, Universidad Del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia.

Published: June 2020

Purpose: To report the ophthalmological approach of a patient with Blau syndrome (BS) in Colombia.

Observations: We describe a 9-year-old Colombian boy with sporadic BS due to a nucleotide-binding oligomerization domain containing 2 (NOD2) mutation, who presented with joint and dermatologic symptoms. He was referred to the uveitis service with a single functional eye, due to retinal detachment in the other eye. Despite treatment with corticosteroids, methotrexate, and adalimumab, the patient continued to exhibit progressive disease.

Conclusion: BS-related uveitis is characterized by severe ocular morbidity. Appropriate interdisciplinary treatment is necessary for the correct identification and management of the disease, considering the inherent difficulty in its diagnosis due to its diverse clinical manifestations. The severity of BS-related uveitis in this report highlights the need for more effective therapies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178324PMC
http://dx.doi.org/10.1016/j.ajoc.2020.100714DOI Listing

Publication Analysis

Top Keywords

bs-related uveitis
8
ophthalmological treatment
4
treatment early-onset
4
early-onset sarcoidosis/blau
4
sarcoidosis/blau syndrome
4
syndrome colombian
4
colombian child
4
child case
4
case report
4
report purpose
4

Similar Publications

Objectives: We aimed to determine the prevalence of cardiovascular involvement in our Blau syndrome (BS) cohort and provide detailed analysis of their cardiovascular manifestations and outcome. We also tried to find out the risk factors for developing cardiovascular involvement.

Methods: Clinical manifestations, laboratory findings, and treatments were reviewed.

View Article and Find Full Text PDF

Objectives: Cerebral venous sinus thrombosis (CVST) is a cerebrovascular disease characterized by thrombosis of the cerebral venous or dural sinuses. Autoimmune diseases (AD) are important causes of CVST. This study aims to reveal the differences between CVST associated with autoimmune diseases compared with other causes (OCs) and Behcet's syndrome (BS) compared with other ADs.

View Article and Find Full Text PDF

Objectives: Behçet's syndrome (BS) is a rare systemic vasculitis often complicated by thrombotic events. Given the lack of validated biomarkers, BS diagnosis relies on clinical criteria.In search of novel biomarkers for BS diagnosis, we determined the profile of plasmatic circulating microRNAs (ci-miRNAs) in patients with BS compared with healthy controls (HCs).

View Article and Find Full Text PDF
Article Synopsis
  • The study assessed the effectiveness of SB5, a biosimilar to adalimumab, for treating uveitis related to Behçet's syndrome (BS).
  • Data from eight BS patients showed that SB5 led to complete control of uveitis in all 16 affected eyes, with no relapses reported during follow-up.
  • The treatment not only resolved retinal vasculitis in all cases but also maintained stable visual acuity, indicating SB5's promising role in managing this condition.
View Article and Find Full Text PDF

Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.

Front Immunol

June 2021

Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, Paris, France.

Objective: Mucocutaneous and joint disorders are the most common manifestations in Behçet's syndrome (BS) and are frequently clustered in the so-called minor forms of BS. There remains a need for safe and effective treatment for joint lesions in BS. We report the long-term safety and effectiveness of apremilast in refractory joint and mucocutaneous manifestations of BS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!